safe. convenient. effective. Revolutionary.
Experience The True Breakthrough In Topical Transdermal Delivery
Product Development Strategy
A-Synaptic Product Development Strategy consists of a portfolio of topical/transdermal prescriptive drugs designed to treat both orphan drug condition as well as major unmet medical need. Currently, the main focus of our research and product development is to create a Cannabinoid based transdermal treatment for pediatric epileptic seizures.
A-Synaptic Inc., has a robust pipeline of various cannabinoid applications to treat serious conditions. We have recently successfully completed a bioavailability human clinical trial authorized by Health Canada which has been published. We are working to structure a Physician-based IND in the United States.